TY - JOUR
T1 - LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker
AU - Chen, Dahu
AU - Sun, Yutong
AU - Wei, Yongkun
AU - Zhang, Peijing
AU - Rezaeian, Abdol Hossein
AU - Teruya-Feldstein, Julie
AU - Gupta, Sumeet
AU - Liang, Han
AU - Lin, Hui Kuan
AU - Hung, Mien Chie
AU - Ma, Li
N1 - Funding Information:
We are grateful to R.A. Weinberg for his advice and reagents. We thank S. Ethier for providing cell lines; F. Reinhardt for advice on mouse surgery; the Genome Technology Core at the Whitehead Institute, the ShRNA and ORFeome Core at MD Anderson Cancer Center and the Histology Core Laboratories at MD Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center for technical assistance; and members of the Ma Lab for discussion. We thank J. Chen, K. Muller, W. Pagel, K. Keyomarsi, L. Li and R. Cleveland for critical reading of the manuscript. This work is supported by the US National Institutes of Health grants R00CA138572 (to L.M.), R01CA166051 (to L.M.), R01CA109311 (to M.-C.H.) and P01CA099031 (to M.-C.H.), a Cancer Prevention and Research Institute of Texas Scholar Award R1004 (to L.M.), a University of Texas STARS Award (to L.M.), a Faculty Development Award (to L.M.) from the MD Anderson Cancer Center Support grant CA016672 from the US National Institutes of Health, Center for Biological Pathways (to Y.S. and M.-C.H.), a Susan G. Komen for the Cure grant SAC110016 (to M.-C.H.), the National Breast Cancer Foundation, Inc. and the Sister Institution Fund of China Medical University and Hospital and MD Anderson Cancer Center (to M.-C.H.).
PY - 2012/10
Y1 - 2012/10
N2 - There is a pressing need to identify prognostic markers of metastatic disease and targets for treatment. Combining high-throughput RNA sequencing, functional characterization, mechanistic studies and clinical validation, we identify leukemia inhibitory factor receptor (LIFR) as a breast cancer metastasis suppressor downstream of the microRNA miR-9 and upstream of Hippo signaling. Restoring LIFR expression in highly malignant tumor cells suppresses metastasis by triggering a Hippo kinase cascade that leads to phosphorylation, cytoplasmic retention and functional inactivation of the transcriptional coactivator YES-associated protein (YAP). Conversely, loss of LIFR in nonmetastatic breast cancer cells induces migration, invasion and metastatic colonization through activation of YAP. LIFR is downregulated in human breast carcinomas and inversely correlates with metastasis. Notably, in approximately 1,000 nonmetastatic breast tumors, LIFR expression status correlated with metastasis-free, recurrence-free and overall survival outcomes in the patients. These findings identify LIFR as a metastasis suppressor that functions through the Hippo-YAP pathway and has significant prognostic power.
AB - There is a pressing need to identify prognostic markers of metastatic disease and targets for treatment. Combining high-throughput RNA sequencing, functional characterization, mechanistic studies and clinical validation, we identify leukemia inhibitory factor receptor (LIFR) as a breast cancer metastasis suppressor downstream of the microRNA miR-9 and upstream of Hippo signaling. Restoring LIFR expression in highly malignant tumor cells suppresses metastasis by triggering a Hippo kinase cascade that leads to phosphorylation, cytoplasmic retention and functional inactivation of the transcriptional coactivator YES-associated protein (YAP). Conversely, loss of LIFR in nonmetastatic breast cancer cells induces migration, invasion and metastatic colonization through activation of YAP. LIFR is downregulated in human breast carcinomas and inversely correlates with metastasis. Notably, in approximately 1,000 nonmetastatic breast tumors, LIFR expression status correlated with metastasis-free, recurrence-free and overall survival outcomes in the patients. These findings identify LIFR as a metastasis suppressor that functions through the Hippo-YAP pathway and has significant prognostic power.
UR - http://www.scopus.com/inward/record.url?scp=84870261155&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870261155&partnerID=8YFLogxK
U2 - 10.1038/nm.2940
DO - 10.1038/nm.2940
M3 - Article
C2 - 23001183
AN - SCOPUS:84870261155
SN - 1078-8956
VL - 18
SP - 1511
EP - 1517
JO - Nature Medicine
JF - Nature Medicine
IS - 10
ER -